Trial
NCT03130764
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Columbia University
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
Durvalumab
Why stopped
PI Transferred
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-06